Isomorphic Labs Closes $5 Billion Series C With Alphabet's Backing
Isomorphic Labs closed a $5 billion Series C and signed a cancer drug deal with Merck, while Novartis and Sanofi report faster AI-driven discovery cycles.
AI SummaryAI
- Isomorphic Labs closed a $5 billion Series C on November 17, co-led by Greenoaks and Sequoia Capital.
- Isomorphic Labs and Merck signed a cancer small-molecule deal using the IsoDDE system on November 19.
- A $2.1 billion Series B in May lifted Isomorphic Labs fundraising to $7.1 billion in six months.
- Novartis cut project start to candidate nomination from about three years to 18–24 months, Fiona Marshall said.
Alphabet Backs Another $5 Billion Bet
Isomorphic Labs, the drug discovery company spun out of Google DeepMind and backed by Alphabet, closed a $5 billion Series C round on November 17 and followed it with a cancer research deal signed with Merck two days later, a pairing that makes the company one of the best-capitalized players in AI drug design. The round was co-led by Greenoaks and Sequoia Capital, with Alphabet investing again. Isomorphic Labs had already raised $2.1 billion in a Series B in May, so the two rounds total $7.1 billion within roughly six months. New capital is earmarked for expanding the AI drug design platform, laboratory capacity and the in-house pipeline, with the stated goal of pushing more designed candidates into human trials. The Merck agreement, signed on November 19, covers a single oncology target. Isomorphic Labs will apply its IsoDDE design system to proprietary data supplied by Merck, which takes charge of preclinical development, clinical trials, manufacturing and commercialization. The contract includes an upfront payment, research and commercialization milestones and royalties on future sales; neither side disclosed the amounts. Earlier deals show how this structure pays out. In 2024, Eli Lilly and Novartis signed research agreements with the company carrying upfront payments of $45 million and $37.5 million respectively, with potential milestone payments of up to $2.9 billion combined. Pharmaceutical groups are clearly willing to pay upfront for design capacity today, but how much of the milestone money ever lands depends on candidates clearing development, approval and commercialization targets step by step.
Novartis and Sanofi Quantify Faster Discovery
The funding wave is landing alongside the first hard efficiency numbers from large pharma. Novartis biomedical research head Fiona Marshall said the average time from launching a project to nominating a development candidate has fallen from about three years to 18–24 months, with AI helping teams analyze biological data, screen potential targets and select molecules worth testing further. Sanofi supplied a second case: AI-assisted analysis of early study data for its asthma drug lunsekimig let the company make its dose selection decision earlier and drop one planned clinical trial, saving at least a year. Sanofi's chief computing and AI officer, Matt Truppo, expects AI to shorten early discovery cycles by 20–25% within two years and by roughly half within five years across more than 100 projects, a forecast rather than an achieved average. The two gains sit at different stages of the funnel. Novartis compressed project start to candidate nomination; Sanofi used existing data to eliminate a study outright. Shorter timelines move programs to the next phase sooner and can trim some experiment costs, though savings do not map directly onto total spend once late-stage trials consume the bulk of a budget. Success rates remain the open question. A review published in Cancer Treatment Reviews in October 2026 counted 129 AI-related candidates from 69 companies that had entered human trials as of March 1, most still early stage, with an observed Phase II success rate of about 19.5% in the sample. The authors caution that the figure does not yet prove AI-designed drugs outperform conventional discovery, since many programs are unfinished and the sample mixes disease areas and stages. The closest live test is Insilico Medicine's Rentosertib for idiopathic pulmonary fibrosis, built with AI in both target discovery and molecule design. In a Phase IIa trial of 71 patients published in Nature Medicine in 2025, forced vital capacity rose an average of 98.4 milliliters at the highest dose after 12 weeks while the placebo group fell 20.3 milliliters. Phase III dosing began in September 2026, enrolling about 320 patients for a 52-week study; the drug is not yet approved.
129 Candidates, Thin Clinical Proof
Our reading of the week is that the story has shifted from round size to commercial demand: recurring upfronts and milestone income track how much work pharma actually hands to AI platforms far better than headline fundraising totals. The confirmed progress sits in discovery and early research, where Novartis and Sanofi have produced quantified, stage-specific results. Clinical success rates have no comparable proof yet, which keeps the 19.5% Phase II observation a sample statistic rather than a verdict on the technology. The Phase III readout for Rentosertib, running in roughly 320 patients over 52 weeks, will examine the thesis more directly than any valuation, and both the pace of new pharma deals and the willingness of partners to accept milestone-heavy terms will show whether the $7.1 billion in fresh capital reflects durable demand or momentum.
AI-generated, AI-reviewed, under COINOTAG editorial oversight.

